ZebraSci

Executive Summary

ZebraSci is a specialized contract research organization (CRO) focused on drug-device combination products, a critical and growing segment in pharmaceuticals. Founded in 2009 and headquartered in Cambridge, MA, the company offers analytical testing, container closure integrity, and device performance services to pharmaceutical and biotech clients. In 2023, ZebraSci was acquired by BD (Becton, Dickinson and Company), a global medical technology leader. This acquisition enables ZebraSci to leverage BD's vast resources, distribution network, and expertise in drug delivery devices while maintaining its independent platform. The combination creates a comprehensive service offering for clients developing pre-filled syringes, autoinjectors, and other combination products. The market for these products is expanding due to the rise of biologics and self-administration trends, positioning ZebraSci for steady demand. However, as a private entity under BD, its growth is tied to BD's strategic priorities and internal investment decisions. The company benefits from regulatory tailwinds emphasizing container closure integrity and device functionality. Overall, ZebraSci occupies a defensible niche with moderate growth potential.

Upcoming Catalysts (preview)

• Q3 2026Expansion of analytical testing services for high-growth drug-device formats (e.g., wearable injectors)80% success
• TBDSecuring new multi-year contracts with top-20 pharmaceutical companies for combination product testing75% success
• Q3 2026Regulatory updates (e.g., FDA guidance on container closure integrity testing) driving increased demand for ZebraSci's expertise70% success